Global InformationCefiderocol information
 | |
| Clinical data | |
|---|---|
| Trade names | Fetroja, Fetcroja |
| Other names | RSC-649266 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620008 |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Siderophore cephalosporins |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 56–58%[4] |
| Elimination half-life | 2.8 hours |
| Excretion | mainly kidney (60–70% unchanged) |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| Chemical and physical data | |
| Formula | C30H34ClN7O10S2 |
| Molar mass | 752.21 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available.[5] It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa.[6][7][8] It is given by injection into a vein.[1]
Common side effects include diarrhea, infusion site reactions, constipation and rash.[9]
Cefiderocol is in the cephalosporin family of medications.[5][10] It was approved for medical use in the United States in November 2019, and in the European Union in April 2020.[5][11][2] In September 2020, cefiderocol (Fetroja) received FDA approval[12] as supplemental New Drug Application (sNDA) for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) when caused by Gram-negative bacteria resistant to other antibiotics. It is on the World Health Organization's List of Essential Medicines.[13]
- ^ a b "Fetroja- cefiderocol sulfate tosylate injection, powder, for solution". DailyMed. 19 November 2019. Retrieved 29 April 2020.
- ^ a b Cite error: The named reference
Fetcroja EPARwas invoked but never defined (see the help page). - ^ "Fetcroja Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C (May 2017). "Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment". Journal of Clinical Pharmacology. 57 (5): 584–591. doi:10.1002/jcph.841. PMC 5412848. PMID 27874971.
- ^ a b c Cite error: The named reference
FDA2019was invoked but never defined (see the help page). - ^ Choi JJ, McCarthy MW (February 2018). "Cefiderocol: a novel siderophore cephalosporin". Expert Opinion on Investigational Drugs. 27 (2): 193–197. doi:10.1080/13543784.2018.1426745. PMID 29318906. S2CID 205768562.
- ^ Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S, et al. (July 2018). "Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship". European Journal of Medicinal Chemistry. 155: 847–868. doi:10.1016/j.ejmech.2018.06.014. PMID 29960205. S2CID 49682995.
- ^ Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JC, Ariyasu M, et al. (December 2018). "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial". The Lancet. Infectious Diseases. 18 (12): 1319–1328. doi:10.1016/S1473-3099(18)30554-1. PMID 30509675. S2CID 54552812.
- ^ "Drug Trials Snapshot: Fetroja". U.S. Food and Drug Administration (FDA). 14 November 2019. Retrieved 29 April 2020.
This article incorporates text from this source, which is in the public domain.
- ^ Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. (February 2019). "Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli". Drugs. 79 (3): 271–289. doi:10.1007/s40265-019-1055-2. PMID 30712199. S2CID 59541210.
- ^ "Drug Approval Package: Fetroja (cefiderocol)". U.S. Food and Drug Administration (FDA). 19 December 2019. Retrieved 29 April 2020.
- ^ "FDA Approves Fetroja (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia". Drugs.com. Retrieved 29 September 2020.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
